文献速递流行病学与生物统计临床试验与 GCP

血浆置换对ANCA相关性血管炎患者的影响:一项更新的系统综述与Meta分析

The effects of plasma exchange in patients with ANCA-associated vasculitis: an updated systematic review and meta-analysis.
PubMed 文献 · BMJ · 2022-02-25

该系统综述与Meta分析纳入9项随机对照试验共1060例ANCA相关性血管炎患者,评估血浆置换对全因死亡、终末期肾病、严重感染等结局的影响。结果显示血浆置换对全因死亡无重要影响(RR 0.90,95%CI 0.64-1.27),降低12个月终末期肾病风险(RR 0.62,95%CI 0.39-0.98),但增加12个月严重感染风险(RR 1.27,95%CI 1.08-1.49)。

要点

  • 血浆置换对ANCA相关性血管炎患者全因死亡无重要影响(RR 0.90,95%CI 0.64-1.27)。
  • 血浆置换降低12个月终末期肾病风险(RR 0.62,95%CI 0.39-0.98)。
  • 血浆置换增加12个月严重感染风险(RR 1.27,95%CI 1.08-1.49)。

核心结论

  • 在ANCA相关性血管炎治疗中,血浆置换对死亡率无重要影响,降低12个月终末期肾病风险,但增加严重感染风险。

研究设计与样本

  • 系统综述与随机对照试验的Meta分析,纳入9项试验共1060例ANCA相关性血管炎或寡免疫复合物型急进性肾小球肾炎患者,随访至少12个月。
  • 检索Medline、Embase和CENTRAL至2020年7月,由评价者独立筛选研究、提取数据并使用Cochrane偏倚风险工具评估偏倚风险。
  • 采用随机效应模型计算风险比和95%置信区间,并按GRADE方法总结证据质量。

主要发现

  • 全因死亡:血浆置换组与对照组相比无重要影响,相对风险0.90(95%CI 0.64-1.27),中等确定性。
  • 终末期肾病:来自7项试验共999例报告终末期肾病的数据显示,血浆置换降低12个月终末期肾病风险,相对风险0.62(95%CI 0.39-0.98),中等确定性,无亚组效应证据。
  • 严重感染:来自4项试验共908例的数据显示,血浆置换增加12个月严重感染风险,相对风险1.27(95%CI 1.08-1.49),中等确定性。
  • 其他结局:血浆置换对其他结局的影响不确定或被认为对患者不重要。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 事件相对稀疏,因此治疗效应估计不精确。
  • 无法评估参与者水平的亚组效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the effects of plasma exchange on important outcomes in anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV). DESIGN: Systematic review and meta-analysis of randomised controlled trials. ELIGIBILITY CRITERIA: Randomised controlled trials investigating effects of plasma exchange in patients with AAV or pauci-immune rapidly progressive glomerulonephritis and at least 12 months' follow-up. INFORMATION SOURCES: Prior systematic reviews, updated by searching Medline, Embase, and CENTRAL to July 2020. RISK OF BIAS: Reviewers independently identified studies, extracted data, and assessed the risk of bias using the Cochrane Risk of Bias tool. SYNTHESIS OF RESULTS: Meta-analyses were conducted using random effects models to calculate risk ratios and 95% confidence intervals. Quality of evidence was summarised in accordance with GRADE methods. Outcomes were assessed after at least12 months of follow-up and included all-cause mortality, end stage kidney disease (ESKD), serious infections, disease relapse, serious adverse events, and quality of life. RESULTS: Nine trials including 1060 participants met eligibility criteria. There were no important effects of plasma exchange on all-cause mortality (relative risk 0.90 (95% CI 0.64 to 1.27), moderate certainty). Data from seven trials including 999 participants that reported ESKD demonstrated that plasma exchange reduced the risk of ESKD at 12 months (relative risk 0.62 (0.39 to 0.98), moderate certainty) with no evidence of subgroup effects. Data from four trials including 908 participants showed that plasma exchange increased the risk of serious infections at 12 months (relative risk 1.27 (1.08 to 1.49), moderate certainty). The effects of plasma exchange on other outcomes were uncertain or considered unimportant to patients. LIMITATIONS OF EVIDENCE: There is a relative sparsity of events, and treatment effect estimates are therefore imprecise. Subgroup effects at the participant level could not be evaluated. INTERPRETATION: For the treatment of AAV, plasma exchange has no important effect on mortality, reduces the 12 month risk of ESKD, but increases the risk of serious infections. FUNDING: No funding was received. REGISTRATION: This is an update of a previously unregistered systematic review and meta-analysis published in 2014.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Walsh M, Collister D, Zeng L, et al. The effects of plasma exchange in patients with ANCA-associated vasculitis: an updated systematic review and meta-analysis. BMJ. 2022. PMID: 35217545. doi:10.1136/bmj-2021-064604

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。